These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6453154)

  • 1. H-2 restriction of adoptive immunotherapy of advanced tumors.
    Greenberg PD; Cheever MA; Fefer A
    J Immunol; 1981 Jun; 126(6):2100-3. PubMed ID: 6453154
    [No Abstract]   [Full Text] [Related]  

  • 2. Alloimmunization and adoptive immunotherapy of leukemia.
    Truitt RL; Shih CY; Rimm AA; Tempelis LD; Bortin MM
    Transplant Proc; 1981 Dec; 13(4):1910-4. PubMed ID: 6949385
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies of the mechanisms for the induction of in vivo tumor immunity. III. Recruitment of host helper cells by donor T cells in adoptive transfer of cell-mediated immunity.
    Ting CC; Rodrigues D; Igarashi T
    J Immunol; 1979 Apr; 122(4):1510-8. PubMed ID: 221575
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: II. Comparison of cells cultured with and without tumor to noncultured immune cells.
    Cheever MA; Greenberg PD; Fefer A
    J Immunol; 1978 Dec; 121(6):2220-7. PubMed ID: 152790
    [No Abstract]   [Full Text] [Related]  

  • 5. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
    Cheever MA; Greenberg PD; Fefer A
    Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloned helper and cytotoxic T lymphocytes as effector cells in adoptive immunotherapy of murine leukemia.
    Bookman MA; Horak E; de Graaf PW
    Prog Clin Biol Res; 1989; 288():141-9. PubMed ID: 2524069
    [No Abstract]   [Full Text] [Related]  

  • 7. H-2 restriction of the T cell response to chemically induced tumors: evidence from F1 replaced by parent chimeras.
    Lannin DR; Yu S; McKhann CF
    J Immunol; 1982 Jan; 128(1):263-8. PubMed ID: 6459368
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro.
    Cheever MA; Kempf RA; Fefer A
    J Immunol; 1977 Aug; 119(2):714-8. PubMed ID: 886192
    [No Abstract]   [Full Text] [Related]  

  • 9. [Inhibition of the effect of immunocytotherapy in leukemia in mice under stress and the possibilities of its withdrawal].
    Sukhikh GT
    Biull Eksp Biol Med; 1984 Dec; 98(12):694-6. PubMed ID: 6542442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response to weakly immunogenic virally induced tumors. IV. Dissociated recognition of H-2 and tumor-associated antigens.
    Devens B; Naor D; Kedar E
    Transplantation; 1979 Nov; 28(5):389-95. PubMed ID: 160637
    [No Abstract]   [Full Text] [Related]  

  • 11. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal analysis of the T lymphocyte response to murine sarcoma virus-induced tumors.
    Brunner KT; Weiss A; Cerottini JC; MacDonald HR
    Transplant Proc; 1982 Sep; 14(3):556-8. PubMed ID: 6217605
    [No Abstract]   [Full Text] [Related]  

  • 13. The in vitro generation of H-2-restricted cytotoxic T cells to AKR/Gross leukemia virus-induced tumors. I. Requirement for stimulation with allogeneic leukemia cells in vivo.
    Green WR
    J Immunol; 1982 Mar; 128(3):1043-9. PubMed ID: 6976986
    [No Abstract]   [Full Text] [Related]  

  • 14. T cell tolerance in moloney-murine leukemia virus (M-MuLV) carrier mice: low cytotoxic T lymphocyte precursor frequency and absence of suppressor T cells in carrier mice with Moloney-murine sarcoma (M-MSV)-induced tumors.
    Collavo D; Ronchese F; Zanovello P; Biasi G; Chieco-Bianchi L
    J Immunol; 1982 Feb; 128(2):774-9. PubMed ID: 6459385
    [No Abstract]   [Full Text] [Related]  

  • 15. Specific adoptive immunotherapy.
    Greenberg PD; Klarnet JP; Kern DE; Okuno K; Riddell S; Cheever MA
    Prog Clin Biol Res; 1989; 288():349-61. PubMed ID: 2785692
    [No Abstract]   [Full Text] [Related]  

  • 16. New immunological approaches to the application of BCG vaccine for the treatments of tumors (acute leukoses).
    Ter-Grigorov VS; Yablokova TB; Levy DT; Rosenberg AM; Pisarenko NN; Levewbook IS; Graff IA
    J Hyg Epidemiol Microbiol Immunol; 1976; 20(1):25-31. PubMed ID: 57195
    [No Abstract]   [Full Text] [Related]  

  • 17. Adoptive chemoimmunotherapy of cancer in animals: a review of results, principles, and problems.
    Fefer A; Einstein AB; Cheever MA
    Ann N Y Acad Sci; 1976; 277(00):492-504. PubMed ID: 793486
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolonged survival in long-passage AKR leukemia using chemotherapy, radiotherapy, and adoptive immunotherapy.
    Bortin MM; Rimm AA; Rodey GE; Giller R; Saltzstein EC
    Cancer Res; 1974 Aug; 34(8):1851-6. PubMed ID: 4152270
    [No Abstract]   [Full Text] [Related]  

  • 19. Effector mechanisms by which adoptively transferred T cells promote tumor eradication.
    Greenberg PD; Kern DE; Jensen MC; Klarnet JP; Cheever MA
    Prog Clin Biol Res; 1987; 244():127-35. PubMed ID: 2958868
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential regulation of H-2 antigen expression in tumors and its biologic consequences.
    Schmidt W; Alonso A; Leben L; Festenstein H
    Transplant Proc; 1981 Dec; 13(4):1814-8. PubMed ID: 7330969
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.